Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. It blocks viral entry into host cells while preserving normal immunologic function. The Company is also investigating an intramuscular method of administration of Trogarzo. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy.


TSX:TH - Post by User

Comment by Wino115on Jan 15, 2021 10:40pm
173 Views
Post# 32312385

RE:RE:RE:RE:RE:Why did they do this horrible offering?

RE:RE:RE:RE:RE:Why did they do this horrible offering?While that's a lot of after market, sometimes it seems it's just the print of a prior trade. I have never understood those after hour trades in an illiquid microcap. There usually seems to be gaps on either side of those after hour or premarket trades.  It's never continuous.  Guess we'll see, but I think it may be more white noise and hopefully I'm not whistling past the graveyard on that. 

I'm repeating myself on the deal, but I think it highlights the lack of financial market sophistication on the BOD and the CFO office. Clearly the risk aversion triggered it all and so I don't put all the blame on the CFO.  But I base that opinion on the fact the CEO isn't a capital market guy (although he was on Pfizer earnings calls often), the BOD doesn't have much, the Can/US markets are very different and massively different in size/complexity/scope and they have literally zero experience there except the IR position and that's from a different angle. They should definitely bone-up in that category.

On the EMA, I'm really not sure. In one way, I think the big nugget is the US first anyway. It could be they would partner out that portion with a Euro firm and bring in some cash that way and give them the rights to sell there. It was just key to get one of them on board to start and given the timeline, if one starts 2-3-4 months ahead of another, you can still get pretty close to each other by the end.  We know the FDA has  been changing their thinking, so if anything that was the harder "yes" and the EMA hasn't changed. So it could be they know that in satisfying the FDA, it will be at least what the EMA wants if not more.  That seems likely to me and I'm not sure why once they have it figured out at the FDA, they wouldn't then go back and say, okay here's our final plan that harmonizes the round 1 issues identifies and meets all the FDA issues (where we had to tweak) and all yours.  Do you approve?  That makes more sense to me given which bodies have shifted and which haven't. We just need one to start and if the other follows a few months later that's not a big deal to me.  The balls still rolling downhill at that point.

<< Previous
Bullboard Posts
Next >>

USER FEEDBACK SURVEY ×

Be the voice that helps shape the content on site!

At Stockhouse, we’re committed to delivering content that matters to you. Your insights are key in shaping our strategy. Take a few minutes to share your feedback and help influence what you see on our site!

The Market Online in partnership with Stockhouse